Companies: 10,795·Total market cap: $144.5T
Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.

OCULNASDAQHealthcare● Active
$8.32
+$0.07(+0.88%)
Market Cap$1.8B
P/E Ratio
52W High$16.44
52W Low$6.23
Overview

Ocular Therapeutix, Inc. (OCUL) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · OCUL · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.46ocul eps ttm · ocul earnings per shareEarnings history
PE Ratio (TTM)ocul pe ratio ttm · ocul price to earningsPE Ratio deep dive
Revenue (TTM)$52.0Mocul revenue ttm · ocul annual revenueFull revenue history
Dividend YieldNo Dividenddoes ocul pay dividends · ocul dividend yieldDividend history
Shares Outstanding187.2Mocul shares outstanding · ocul floatShares outstanding history
Next EarningsAug 4, 2026Est.ocul earnings date · ocul next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$51.8M▼ 18.67% YoY
202320242025
ocular therapeutix, inc. revenue · ocul revenue 2025
FY 2025Net Income-$265.9M▼ 37.43% YoY
202320242025
ocular therapeutix, inc. net income · ocul profit 2025
FY 2025EPS$-1.42▼ 16.39% YoY
202320242025
ocul eps · ocular therapeutix, inc. earnings per share 2025
TTM:Revenue: $52.0MNet Income: -$290.5MEPS: $-1.46View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy19 analystsis ocul a buy · ocul analyst rating
Strong Buy
1
Buy
16
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$30.00Low
$8.32Current
$30.00Avg Target260.47% upside
$30.00High
ocul price target · ocul 12 month forecast

Total: 19 · Buy rate: 89.5%

The OCUL analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $30.00, representing +260.47% upside from the current price of $8.32.

Stock Performance

Full History
1D+0.30%
1W+1.29%
1M-14.25%
3M-19.43%
YTD-31.84%
1Y-7.02%
5Y-44.57%

About Ocular Therapeutix, Inc.

CEOPravin U. Dugel
IPO DateJul 25, 2014
Employees274
CountryUS
Websiteocutx.com

Ocular Therapeutix, Inc. a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrog…

what is ocular therapeutix, inc. · ocul stock overview · ocular therapeutix, inc. company profile · who is ocular therapeutix, inc. ceo · ocul NASDAQ · ocular therapeutix, inc. headquarters · ocular therapeutix, inc. business segments

About Stock Overview & Key Data

Ocular Therapeutix, Inc. (OCUL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 25, 2014. As of the latest trading session, OCUL stock price is $8.32, with a market capitalization of $1.8B. The stock has returned -7.02% over the past 12 months and -31.84% year-to-date.

According to 19 Wall Street analysts, the consensus rating for Ocular Therapeutix, Inc. stock is Buy, with an average 12-month price target of $30.00. In fiscal year 2025, Ocular Therapeutix, Inc. reported revenue of $51.8M and net income of -$265.9M. For detailed data — including Ocular Therapeutix, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Ocular Therapeutix, Inc. (OCUL) stock price is $8.32. The stock is traded on NASDAQ under the ticker symbol OCUL. The 52-week range is $6.23 – $16.44.

OCUL stock priceOCUL quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice